Skip to content

Goldman Sachs’s Buyout Arm Agrees $2 Billion Deal for Norgine

  • US firm wins auction process for speciality pharma group
  • Goldman’s PE arm outbid at least two other buyout firms
Updated on

Goldman Sachs Group Inc.’s private equity arm has agreed to buy a controlling stake in Norgine BV from the specialty pharmaceutical company’s founding Stein family.

The deal was announced in a statement Thursday that confirmed an earlier Bloomberg News report. Financial terms weren’t disclosed. The purchase values Amsterdam-based Norgine at about 1.8 billion euros ($1.9 billion), according to people familiar with the matter.